Short Interest Decreases By 13% For KERX

The most recent short interest data has been released by the NASDAQ for the 01/31/2014 settlement date, which shows a 2,188,800 share decrease in total short interest for Keryx Biopharmaceuticals Inc. ( KERX), to 14,834,316, a decrease of 12.86% since 01/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for KERX at the 01/31/2014 settlement increased to 5,376,970, as compared to 2,340,191 at the 01/15/2014 report. That brought "days to cover" down to 2.76, a 62.07% decrease from the 7.27 days to cover calculated at the previous short interest data release.

Top 25 S.A.F.E. Dividend Stocks »

The below chart shows the historical "days to cover" for KERX at previous short interest release dates:

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where KERX had been shorted as a hedge.

The chart below shows the one year performance of KERX shares, versus its 200 day moving average. Looking at this chart, KERX's low point in its 52 week range is $6.33 per share, with $16.21 as the 52 week high point — that compares with a last trade of $15.38.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

5 Breakout Stocks Under $10 Set to Soar

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)